Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

An expert summarizes that the emerging concept of broad immune potentiation—exemplified by therapies like Terra-002—seeks to activate multiple immune pathways for a more durable antitumor response in ...

Jansen stresses that testosterone is not a cure-all and often requires adjunct evaluation and management of other conditions such as sleep apnea or thyroid disorders.

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

Preclinical data shared during the 4th Annual Targeted Radiopharmaceuticals Summit (TRP) in San Diego, California, showed that the targeted radiotherapy ATNM-400 achieved robust antitumor efficacy in ...

Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular ...

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.

An expert summarizes that TARA-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in ...

On July 17, 2025, a panel of experts convened by the FDA voiced growing consensus that the boxed warning on menopausal hormone therapies, particularly low-dose vaginal estrogen, is an outdated or ...

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on the newly FDA-approved Neuspera integrated ...

"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD. On July 17, 2025, a panel of experts convened by the FDA outlined the growing ...